Open AccessMesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis
Author(s) -
Luke Barry,
Grainne Crealey,
Paul Cockwell,
Stephen J. Elliman,
Matthew Griffin,
Alexander P. Maxwell,
Timothy O’Brien,
Norberto Perico,
Ciarán O’Neill
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0274136
Subject(s) - medicine , cost effectiveness analysis , cohort , quality adjusted life year , mesenchymal stem cell , incremental cost effectiveness ratio , cost effectiveness , oncology , pathology , risk analysis (engineering)